News & Updates

Treatment with methylprednisolone reduces the risk of kidney composite outcomes, including kidney failure, 40 percent decline in eGFR, or death due to kidney disease, in patients with IgA nephropathy (IgAN), according to the TESTING* study presented at ASN Kidney Week 2021.

Among patients who received 6 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), switching to a single antiplatelet therapy (SAPT) regimen for another 6 months resulted in less gastrointestinal (GI) injury than continuing DAPT, results of the OPT-PEACE trial showed.

Cyproheptadine appears to induce hunger in adults with poor appetite, as shown in a study.

Treatment with the RNAi therapeutic lumasiran led to a significant reduction in plasma oxalate and pre-dialysis oxalate levels in patients with advanced primary hyperoxaluria type 1 (PH1), according to the 6-month primary analysis of phase III ILLUMINATE-C trial presented at ASN Kidney Week 2021.

The oral HIF-PHI* daprodustat was noninferior to standard treatment with erythropoiesis-stimulating agents (ESAs) for increasing haemoglobin levels to within target range, without increasing cardiovascular (CV) risk in patients with anaemia due to chronic kidney disease (CKD), regardless of whether they were dialysis dependent or not, according to the phase III ASCEND-D/-ND trials presented at ASN 2021.

Racecadotril 30 mg powder for oral suspension

Saccharomyces boulardii, fibersol-2, inulin, isomalto-oligosaccharide, magnesium stearate cap

Isotonic seawater solution

The anti–interleukin (IL)-4/-13 antibody dupilumab led to sustained improvements across symptomatic, histologic, and endoscopic measures of eosinophilic oesophagitis (EoE) out to 52 weeks, according to additional data from the LIBERTY EoE TREET trial presented at ACG 2021.